Domestic Inactivated Subunit Influenza Vaccine Grippol® Plus: Safety And Efficacy In Infants Aged 6 Months To 3 Years Old
The paper presents the results of a clinical trial of the safety and efficacy of the vaccine Grippol® plus twice administered in doses of 0,25 ml (n = 70) and 0,5 ml (n = 70) at a 21-day interval in children aged 6 months to 3 years. This is a randomized, double-blind controlled, parallel-group comparative study. The vaccine Grippol® plus twice administered in doses of 0,25 and 0,5 ml in children aged 6 months to 3 years has been ascertained to have a weak reactogenicity and a pronounced immunological activity.